Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-26

Study Completion Date

2024-04-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Montelukast Therapy on Alzheimer's Disease

NCT03991988

Alzheimer Disease

COMPLETED PHASE2

A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

NCT03462121

Mild to Moderate Dementia Due to Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

COMPLETED PHASE2

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

NCT00422981

Mild Cognitive Impairment, So Stated

COMPLETED PHASE2

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059

Alzheimer's Disease

COMPLETED PHASE2

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00257673

Alzheimer's Disease

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease. Study drug (montelukast or matching placebo) will be administered once or twice daily for 26 weeks, and treatment effect will be assessed primarily using the global NTB composite score at Week 26.

Patients who consent to participate will undergo screening assessments to determine eligibility. This study will enroll patients who are ≥50 years of age with mild to moderate Alzheimer's Disease and on a stable treatment of donepezil, rivastigmine or galantamine for ≥3 months. Patients will be randomized (using a balanced block randomization schedule) to one of two treatment groups:

* Group A: Montelukast buccal film
* Group B: Matching placebo buccal film

In addition to the global NTB composite, patients will also be evaluated using the MMSE, ADCS-CGIC, ADCS-ADL23, NPI and S-STS. Patients will be followed for any safety concerns throughout the study and for 4 weeks following the last study visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.

Group Type EXPERIMENTAL

Montelukast buccal film

Intervention Type DRUG

Film with active investigational product (montelukast) inserted and applied on inner cheek

Group B

Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.

Group Type PLACEBO_COMPARATOR

Placebo buccal film

Intervention Type OTHER

Film with placebo (no active drug) inserted and applied on inner cheek

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Montelukast buccal film

Film with active investigational product (montelukast) inserted and applied on inner cheek

Intervention Type DRUG

Placebo buccal film

Film with placebo (no active drug) inserted and applied on inner cheek

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mild to moderate Alzheimer's Disease.
* MMSE score of 14 - 22
* CT or MRI within 18 months prior to screening indicating clinical phenotype of Alzheimer's Disease
* Treated daily with donepezil, rivastigmine or galantamine for ≥ 3 months
* All other medications for chronic conditions should have been at a stable dose for at least 2 weeks prior to first dose.
* No clinically meaningful abnormalities on electrocardiogram (ECG), physical examination and clinical laboratory tests

Exclusion Criteria

* Taken memantine within 2 months prior to screening.
* Current diagnosis of any psychiatric disorder, depression that is not well-controlled, clinically significant or unstable systemic disease, or severe medical procedures
* Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation.
* Patients at imminent risk of self-harm, based on clinical interview and response on S-STS
* History of malignancy occurring within 5 years immediately prior to screening, except for a subject who has been adequately treated for (1) basal cell or squamous cell skin cancer, (2) in situ cervical cancer, (3) localized prostate carcinoma, or (4) who has undergone potentially curative therapy with no evidence of recurrence for more than 3 years post-therapy, and who is deemed at low risk for recurrence by her/his treating physician
* History of any of the following cardiovascular conditions that an unstable:

* Hypotension
* Hypertension
* Active cardiovascular disease
* Evidence of cerebrovascular disease
* Have used or plan to use the following medications from 30 days prior to Visit 1 through the end of the study:

* Narcotic analgesics more frequently than on three days per week as needed for pain;
* Daily antipsychotic (except for risperidone, quetiapine and aripiprazole, and only if at a stable and controlled dose)
* Daily anxiolytic use; however, occasional use as needed for acute agitation or to be used as a rescue anxiolytic (i.e., lorazepam and oxazepam) is acceptable as long as not used within 24 hours of a clinic visit window;
* Daily antidepressants (except for citalopram, escitalopram, venlafaxine, trazodone, sertraline, and mirtazapine, and only if at a stable and controlled dose);
* Low potency antipsychotic agents (eg chlorpromazine) - not permitted at any time during the study;
* Anti-parkinson's disease medications (selegiline, levodopa, amantadine) for the treatment of Parkinson's Syndrome Complex;
* Lithium;
* Clozapine;
* Previously treated with or currently using montelukast

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No